Caffeine and Progression of Parkinson Disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Caffeine use is negatively associated with the risk of developing Parkinson disease (PD) and is protective in animal models of PD, but the relationship between caffeine intake and rate of progression of PD is unknown. We assessed this relationship using data from 2 recent clinical trials of PD. METHODS: Data were ascertained from 2 recent 1-year clinical trials that together included 413 early PD subjects who did not require symptomatic therapy at the time of study entry. Exploratory analyses compared caffeine intake with rate of progression of PD, as measured by either the likelihood of progression to the point of requiring symptomatic therapy or by change in the total Unified Parkinson Disease Rating Scale score. RESULTS: Rate of progression of PD did not differ significantly between those in the highest and lowest quartiles for caffeine use for either of the primary measures or for secondary analyses of changes in scores on the motor or activities of daily living subsections of the Unified Parkinson Disease Rating Scale. Other secondary analyses yielded variable results. CONCLUSIONS: These data do not reveal a consistent relationship between caffeine intake and rate of progression of PD by these measures, although a larger study is required for sufficient power to more fully assess this relationship.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 1×
“Adenosine receptor blockade in humans occurs at caffeine doses as low as 100 mg, about 20-fold lower than doses required for phosphodiesterase inhibition, and a dose that can be achieved by a single 6-ounce cup of coffee.(16,17) Although the lower quartile cutoff for daily caffeine intake was less than 100 mg for both…”
BackgroundYusuf, S. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470010097038 · Cited by 1,014 · cited 1×
“As a results, subgroup analyses for each treatment group were conducted (Table 3) following established guidelines.(14) In the FS1 placebo group, the change in UPDRS score improved by j1.”
MethodAssociation of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 1×
“This negative association is present for caffeinated coffee and for noncoffee sources of caffeine, but is not present for decaffeinated coffee.(2,4)”
BackgroundThe NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: A case-control study
Benedetti, M. D., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2000) · Neurology · doi:10.1212/wnl.55.9.1350 · Cited by 234
Cited by
Neurotoxin-based models of Parkinson's disease
Bové, J., & Perier, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.057 · Cited by 506
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
Caffeine and risk of Parkinson’s disease in a large cohort of men and women
Palacios, N., Gao, X., McCullough, M. L., Schwarzschild, M. A., Shah, R., Gapstur, S., & Ascherio, A. (2012) · Movement Disorders · doi:10.1002/mds.25076 · Cited by 185
“Simon et al.(23) assessed this relationship in a secondary analysis of two clinical trials of PD progression, where caffeine consumption, although not randomized, was measured in a questionnaire.”
Chen, J.-F., & Schwarzschild, M. A. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.10.024 · Cited by 39
“In contrast, a larger (n = 413) but shorter (1-year) study of de novo participants in NET-PD cohorts (FS1 and FS-TOO) [25] reported no consistent association between caffeine intake and motor progression.”
Metadata
- Authors
- Simon, D. K., Swearingen, C. J., Hauser, R. A., Trugman, J. M., Aminoff, M. J., Singer, C., Truong, D., & Tilley, B. C.
- Venue
- Clinical Neuropharmacology
- Published
- 2008-07
- Volume
- 31
- Issue
- 4
- Pages
- 189-196
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2074339384
- Cited by
- 39
- References
- 6
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Caffeine and Progression of Parkinson Disease. https://app.cochat.ai/papers/10.1097/wnf.0b013e31815a3f03
- The paper
- Simon, D. K., Swearingen, C. J., Hauser, R. A., Trugman, J. M., Aminoff, M. J., Singer, C., Truong, D., & Tilley, B. C. (2008). Caffeine and Progression of Parkinson Disease. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0b013e31815a3f03
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.